Fish oil

From Glioblastoma Treatments
Revision as of 04:38, 21 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=Fish Oil (Omega-3 Fatty Acids: EPA and DHA) |FDA_approval=No (Used as a dietary supplement; not specifically FDA-approved for cancer treatment) |used_for=Investigational use in cancer treatment for potential cytotoxic effects and enhancement of chemotherapy and radiation therapy efficacy |clinical_trial_phase=Clinical trials (e.g., advanced cancer study with cachexia, metastatic breast cancer Phase II trial, advanced non-small cell lung cancer...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Fish Oil (Omega-3 Fatty Acids: EPA and DHA)
FDA Approval No (Used as a dietary supplement; not specifically FDA-approved for cancer treatment)
Used for Investigational use in cancer treatment for potential cytotoxic effects and enhancement of chemotherapy and radiation therapy efficacy
Clinical Trial Phase Clinical trials (e.g., advanced cancer study with cachexia, metastatic breast cancer Phase II trial, advanced non-small cell lung cancer trial)
Clinical Trial Explanation Not specified
Common Side Effects Well-tolerated; potential side effects include fishy aftertaste, gastrointestinal discomfort
OS without Malnourished advanced cancer patients: 110 days; adequately nourished patients: 350 days; chemotherapy alone in non-small cell lung cancer: 39% one-year survival
OS with Fish oil supplementation: Malnourished advanced cancer patients: 210 days; adequately nourished patients: 500 days; metastatic breast cancer trial with high-DHA: median survival of 34 months vs. low-DHA: 18 months; non-small cell lung cancer with fish oil: 60% one-year survivalProperty "Has OS with" (as page type) with input value "Fish oil supplementation: Malnourished advanced cancer patients: 210 days; adequately nourished patients: 500 days; metastatic breast cancer trial with high-DHA: median survival of 34 months vs. low-DHA: 18 months; non-small cell lung cancer with fish oil: 60% one-year survival" contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
PFS without Not specified
PFS with Not specifically documented; research highlights increased survival and potential for enhanced treatment efficacy
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: Omega-3 fatty acids, EPA and DHA, from fish oil have shown anti-cancer properties in both lab and clinical settings, including apoptosis induction and chemotherapy/radiation enhancement. Clinical trials indicate fish oil increases survival times and reduces chemotherapy toxicity in patients with advanced cancers, suggesting a beneficial role in cancer therapy. The data underscore the need for additional research to establish efficacy, optimal dosing, and integration into conventional cancer treatment protocols.


From Ben Williams Book: Not specified

Loading comments...